Cannabis Law Report

AUGUST 9, 2021

Cannassure Therapeutics Ltd (TASE: CSURE) (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products, announces today that the company was granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority.

Cannabinoids 98

Cannabinoids Pharmaceutical Treatment Patients 98

Cannabis Law Report

NOVEMBER 12, 2021

” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end. and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

MAY 6, 2022

To: Cannabis Industry Members. Re: Updated List of Pesticides Allowed in the Production of High THC Cannabis. The updated list contains 261 Section 3 pesticides and 88 Section 25(b) pesticides, for a total of 349 products allowed for use in the production of cannabis in Washington State. Bulletin No 22-01. Spray Adjuvants.

THC 52

THC Concentrates Seed-To-Sale Cannabis 52

Cannabis Law Report

OCTOBER 26, 2021

Studies estimate that the number of people suffering from rheumatoid arthritis may rise to over 78 million by 2040. MYMD-1’s primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52